Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GridAI Technologies Corp.AZRX · Entity 7534 | CHIEF SCIENTIFIC OFFICER | July 12, 2018 | July 18, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GridAI Technologies Corp.
Report date July 12, 2018 · Filed July 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,000 |
Reported balance
After 2018-07-12 transaction · row 1
1 source rowRow 1 · 2018-07-12 · Grant · Acquired 15,000 · Balance 15,000 F1: Represents grant of restricted stock. Shares shall vest in increments as follows: 7,500 shares upon the acceptance of a U.S. IND for MS1819, and 7,500 shares upon the the first CF patient dosed with MS1819 anywhere in the globe. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.04 · Expires 2023-06-28 | Direct | 60,000 |
Reported balance
After 2018-07-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-07-12 · Grant · Acquired 60,000 · Balance 60,000 F2: Options with respect to 30,000 shares vest upon the acceptance of a U.S. IND for MS 1819, and the remaining 30,000 shares vest upon the the first CF patient dosed with MS1819 anywhere in the globe. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock. Shares shall vest in increments as follows: 7,500 shares upon the acceptance of a U.S. IND for MS1819, and 7,500 shares upon the the first CF patient dosed with MS1819 anywhere in the globe.
F2: Options with respect to 30,000 shares vest upon the acceptance of a U.S. IND for MS 1819, and the remaining 30,000 shares vest upon the the first CF patient dosed with MS1819 anywhere in the globe.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 12, 2018 Filed Jul 18, 2018 15:57 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantOptions · Derivative | 60,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001415889-18-001122 · form4-07182018_080729.xml · derivative · entry 2 Dupret Daniel · CIK 0001680916 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2023-06-28 F2 · derivative.exercise_date: Options with respect to 30,000 shares vest upon the acceptance of a U.S. IND for MS 1819, and the remaining 30,000 shares vest upon the the first CF patient dosed with MS1819 anywhere in the globe. Read SEC document |
| July 12, 2018 Filed Jul 18, 2018 15:57 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-18-001122 · form4-07182018_080729.xml · nonDerivative · entry 1 Dupret Daniel · CIK 0001680916 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · price: Represents grant of restricted stock. Shares shall vest in increments as follows: 7,500 shares upon the acceptance of a U.S. IND for MS1819, and 7,500 shares upon the the first CF patient dosed with MS1819 anywhere in the globe. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.